Clinical Trial Search

Primary: Change in Worst Lesional Pain in the Past Week Based on Brief Pain Inventory — -2.50; -1.26 units on a scale

Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants

Primary: Changes in Fibroid-related Symptoms After Treatment With Letrozole — -10.42; 1.43 units on a scale — p=0.24

Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…

Primary: Percentage of Subjects Who Are in Amenorrhea at the End of All Four Treatment Courses — 48.7; 60.5 percentage of subjects

Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15

Primary: MRI/MRA of Head/Neck/Chest. — 357 participants

Primary: Percent Change From Baseline in Surface Area of the Lipoma at Six Months — -81.277; 2.053 percentage change from baseline — p=<0.0001

Primary: Frequency of Hepatic Hemangiomas Identified on Abdominal Ultrasound — 24 participants

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Progression-free Survival (PFS) > 6 Months — 0.0 percentage of participants

Primary: Modified Patient and Observer Scar Assessment Scale Color Component Comparing Change From Baseline to Week 12. — -2.33 score on a scale

Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants

Primary: Change in Visible Surface Area of the Lipoma — -31.69; -47.57; -52.42; -66.60 Percent change from baseline

Primary: Number of Participants With a Reduction in Total Tumor Volume of at Least 20%. — 0 Participants

Primary: Number of Adverse Events — 1 Participants